A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Public ClinicalTrials.gov record NCT01454089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Study identification
- NCT ID
- NCT01454089
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Achieve Life Sciences
- Industry
- Enrollment
- 183 participants
Conditions and interventions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Gemcitabine Drug
- OGX-427 1000 mg Drug
- OGX-427 600 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2011
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2014
- Last update posted
- Oct 6, 2016
2011 – 2014
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | — | — |
| Cedars-Sinai Medical Center | Los Angeles | California | — | — |
| University of California Los Angeles | Los Angeles | California | — | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | — | — |
| Radiological Associates of Sacramento | Sacramento | California | — | — |
| Yale University | New Haven | Connecticut | — | — |
| Karmanos Cancer Institute | Detroit | Michigan | — | — |
| Siteman Cancer Center, Washington University School of Medicine | St Louis | Missouri | — | — |
| Urology Cancer Center and GU Research Network | Omaha | Nebraska | — | — |
| Monter Cancer Center | Lake Success | New York | — | — |
| Columbia University Medical Center | New York | New York | — | — |
| Montefiore Medical Center, Albert Einstein College of Medicine | The Bronx | New York | — | — |
| Texas Oncology, P.A. | Dallas | Texas | — | — |
| Seattle Cancer Care Alliance | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01454089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2016 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01454089 live on ClinicalTrials.gov.